Picture of Oxford BioMedica logo

OXB — Oxford BioMedica News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMid CapSucker Stock

Director/PDMR Shareholding

RNS Number : 5685D

Oxford Biomedica PLC

16 October 2025

 

 

PDMR Dealing

Oxford, UK - 16 October 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Natalie Walter, Group General Counsel and Company Secretary of the Company exercised 28,321 LTIP options and 39,679 DBP options at nil exercise price on 14 October 2025 and disposed of 68,000 shares at an average price of £6.116876 per share on 15 October 2025.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.

 

1.Details of thePerson Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)NameNatalie Walter
2.Reason for the notification
a)Position/statusPerson Discharging Managerial Responsibility
b)Initial notification/ amendmentInitial Notification
3.Details of the Issuer
a)Full name of the entityOxford Biomedica plc
b)LEI code213800S1GVQNXQ15K851
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Date of the transaction2025-10-14
b)Description of the financial instrumentOrdinary Shares of 50 pence each
c)Identification codeISIN: GB00BDFBVT43
d)Nature of the transactionExercise of LTIP Options at nil exercise price
e)Place of the transactionLondon Stock Exchange, Main Market (XLON)
f)CurrencyGBP - British pound
g)Price(s) and volumes(s)
Price(s)Volume(s)
£0.0028,321
h)Aggregated information
- Aggregate volume
- Price
- Aggregated total
28,321
£0.00
£0.00
   
1.Details of thePerson Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)NameNatalie Walter
2.Reason for the notification
a)Position/statusPerson Discharging Managerial Responsibility
b)Initial notification/ amendmentInitial Notification
3.Details of the Issuer
a)Full name of the entityOxford Biomedica plc
b)LEI code213800S1GVQNXQ15K851
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Date of the transaction2025-10-14
b)Description of the financial instrumentOrdinary Shares of 50 pence each
c)Identification codeISIN: GB00BDFBVT43
d)Nature of the transactionExercise of DBP Options at nil exercise price
e)Place of the transactionLondon Stock Exchange, Main Market (XLON)
f)CurrencyGBP - British pound
g)Price(s) and volumes(s)
Price(s)Volume(s)
£0.0039,679
h)Aggregated information
- Aggregate volume
- Price
- Aggregated total
39,679
£0.00
£0.00
 
1.Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)NameNatalie Walter
2.Reason for the notification
a)Position/statusPerson Discharging Managerial Responsibility
b)Initial notification/ amendmentInitial Notification
3.Details of the Issuer
a)NameOxford Biomedica plc
b)LEI code213800S1GVQNXQ15K851
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Date of the transaction2025-10-15
b)Description of the financial instrumentOrdinary Shares of 50 pence each
c)Identification codeISIN: GB00BDFBVT43
d)Nature of transactionSale of shares
e)Place of the transactionLondon Stock Exchange, Main Market (XLON)
f)CurrencyGBP - British pound
g)Price(s) and volumes(s)
Price(s)Volume(s)
£6.11687668,000
h)Aggregated information
- Aggregate volume
- Price
- Aggregated total
68,000
£6.116876
£415,947.568
  -Ends-   Enquiries:        OXB: Puja Chopra, Deputy Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com ICR Healthcare: T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / Angela Gray / Davide Salvi   About OXB   OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.   One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.   OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.   OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END     DSHBIBDGLUBDGUU

Recent news on Oxford BioMedica

See all news